Drug Interactions between immune globulin intravenous and moxetumomab pasudotox
This report displays the potential drug interactions for the following 2 drugs:
- immune globulin intravenous
- moxetumomab pasudotox
Interactions between your drugs
immune globulin intravenous moxetumomab pasudotox
Applies to: immune globulin intravenous and moxetumomab pasudotox
MONITOR CLOSELY: Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer. Immune globulin products, particularly those that contain sucrose as a stabilizer and administered at daily doses of 350 to 400 mg/kg or greater, have been associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death. Factors predisposing to acute renal failure include any degree of preexisting renal insufficiency, age greater than 65 years, diabetes mellitus, volume depletion, sepsis, paraproteinemia, and concomitant use of known nephrotoxic drugs.
MANAGEMENT: Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The manufacturers recommend administering immune globulin infusions at the minimum concentration available and at the minimum rate of infusion feasible in such patients. Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter. If renal function deteriorates, discontinuation of the product should be considered. Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.
References
- (2002) "Product Information. Cytogam (cytomegalovirus immune globulin)." CSL Behring LLC
- (2005) "Product Information. Respigam (respiratory syncytial virus immune globulin)." Medimmune Inc
- (2008) "Product Information. BabyBIG (botulism immune globulin)." FFF Enterprises
- (2013) "Product Information. Bivigam (immune globulin intravenous)." Biotest Pharmaceuticals Corporation
- MMWR Morb Mortal Wkly Rep (2013) Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm
- Pusey EY, Levy JB (2013) Nephrotoxicity of intravenous immunoglobulin. http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html
- KDIGO. Kidney Disease Improving Global Outcomes (2013) KDIGO clinical practice guideline for acute kidney injury. http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf
- Guo X, Nzerue C (2013) How to prevent, recognize, and treat drug-induced nephrotoxicity. http://www.ccjm.org/content/69/4/289.full.pdf
- Perazella MA (2013) Renal vulnerability to drug toxicity. http://www.ccjm.org/content/69/4/289.full.pdf
- Naughton CA (2013) Drug-induced nephrotoxicity. http://www.aafp.org/afp/2008/0915/p743.html
- Moses S (2013) Nephrotoxic drugs, drug-induced nephrotoxicity. http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm
Drug and food interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.